市場調查報告書

全球固態腫瘤治療藥市場 - 成長,趨勢,預測(2017年∼2022年)

Solid Tumor Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 391458
出版日期 內容資訊 英文 114 Pages
商品交期: 2-3個工作天內
價格
全球固態腫瘤治療藥市場 - 成長,趨勢,預測(2017年∼2022年) Solid Tumor Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年03月01日內容資訊: 英文 114 Pages
簡介

WHO估計2012年的癌症死者對800萬人。癌症罹患率高的北美及歐洲構成固態腫瘤治療藥市場前幾名佔有率。

本報告提供全球固態腫瘤治療藥市場相關調查,市場概要,癌症的各種類、藥品類型、地區的市場趨勢,市場規模的變化與預測,市場成長要素分析,市場佔有率,競爭情形,主要企業的簡介等,全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 市場定義
  • 基本單位
  • 基本貨幣
  • 調查對象期間與預測
  • 一般調查的前提條件

第2章 調查方法

  • 簡介
  • 分析方法
  • 調查的時間軸
  • 調查的階段
    • 2次調查
    • 討論指南
    • 市場工程 & 計量經濟學模式

第3章 摘要整理

第4章 主要推論

第5章 市場概況和產業趨勢

  • 市場概況
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 市場動態

  • 市場成長要素
    • 癌症盛行率的增加
    • POC檢驗的需求增加
    • 個體化治療藥的需求
    • 分子診斷的增加
    • 醫療制度的變化
  • 市場阻礙因素
    • 法規上的問題
    • 正確的癌症檢測套組的不足
  • 市場機會
    • 生物相似藥的登場
  • 主要課題
    • 熟練的技術人員不足

第7章 全球固態腫瘤治療藥市場:市場區隔

  • 癌症的各類型
    • 乳癌
    • 肺癌
    • 大腸癌
    • 前列腺癌
    • 子宮頸癌
    • 其他
  • 各藥品類型
    • CARBOPLATIN
    • CISPLATIN
    • GEMCITABINE
    • PACLITAXEL
    • DOXORUBICIN
    • BEVACIZUMAB(AVASTIN)
    • ERLOTINIB(TARCEVA)
    • SUNITINIB(SUTENT)
    • EVEROLIMUS(AFINITOR)
    • DOCETAXEL(TAXOTERE)
    • ABIRATERONE ACETATE(ZYTIGA)
    • CABAZITAXEL(JEVTANA)
    • 其他

第8章 全球固態腫瘤治療藥市場:各地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙、葡萄牙
    • 斯堪地那維亞各國
    • 荷比盧三國
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲、紐西蘭
    • 韓國
    • 其他
  • 中東、非洲
    • 波灣合作理事會(GCC)
    • 南非
    • 其他
  • 南美
    • 巴西
    • 阿根廷
    • 其他

第9章 競爭情形

  • M&A分析
  • 新產品的銷售
  • 協定,合作,夥伴關係

第10章 企業簡介

  • AstraZeneca plc
  • Sanofi
  • F. Hoffmann-La Roche Ltd.
  • Biogen Idec, Inc.
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Eli Lilly and Company
  • Kyowa Hakko Kirin
  • Amgen, Inc.
  • Baxter International, Inc.
  • Abbott Laboratories, Inc
  • 其他

第11章 分析師的投資機會預測

第12章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 46411

Market Overview

The solid tumor therapeutics market is expected to register a CAGR of 15% during the forecast period. The major factors that are responsible for the growth of this market include new product approvals in ovarian, pancreatic, and prostate cancers, and increasing government initiatives for cancer awareness. In addition, the other crucial driving factor is the increasing incidence of cancer. For instance, cancer has a significant impact on societies across the world. The most common cancers in 2016 were breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, bladder cancer, melanoma of the skin, non-Hodgkin lymphoma, thyroid cancer, kidney and renal pelvis cancer, leukemia, endometrial cancer, and pancreatic cancer.

Cancer rates could further increase by 50%, to 15 million new cases by 2020, as per the World Cancer Report. It also provides clear evidence that healthy lifestyles and public health action by governments and health practitioners could prevent this trend and prevent as many as one-third of all cancers, worldwide. The American Cancer Society, the leading body in cancer stats and figures, reports 1,685,210 estimated new cancer cases and 595,690 deaths, due to cancer in 2016, in the United States. Hence, the increasing number of patients is expected to drive the market during the forecast period.

However, factors, such as stringent regulatory reforms and price erosion due to generic competition may hinder the growth of this market.

Scope of the Report

Solid tumor therapeutics are pharmaceuticals that specifically treat various cancers, such as breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, and others. Solid tumors are an abnormal mass of tissue that usually does not contain cysts or liquid areas.

Key Market Trends

Breast Cancer is Expected to Hold the Major Revenue Share in the Type of Cancer Segment

Breast cancer is one of the major cancer types for which new immune-based cancer treatments are currently in development. More than 80% of all cancers are caused by solid tumors that grow as a mass of cells in a particular organ, tissue or gland. According to the American Cancer Society, as of 2018, it is estimated that approximately 268,670 new breast cancer cases are expected in the United States. And even several major companies are investing in the development of new treatments for cancers. For example, Ibrance (palbociclib) by Pfizer is for the treatment of ER-positive, HER2-negative breast cancer and has been approved in February 2015. A trial of the use of two drugs in combination found that tumors were completely cleared in 11% of patients with HER2-positive breast cancer and were reduced to a "minimal" size in a further 17%. Nearly 90% saw a reduction in the number of cancer cells. Hence, with the entry of new drugs the segment is expected to continue its lead as the number of cases is also helping in the growth.

North America Dominates the Market and is Expected to do Same in the Forecast Period

North America currently dominates the market for solid tumor therapeutics, and it is expected to continue its stronghold for a few more years. In North America, the United States holds the largest market share. This can be majorly attributed to increasing incidence rates of cancer and increasing awareness among people, and the presence of developed healthcare infrastructure are propelling the growth of the market in the forecast period.

Competitive Landscape

The solid tumor therapeutics market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. With the rising need for cancer treatment and increasing prevalence of cancer. However, the entry of a few smaller players in the market is excepted and they may hold a substantial share. Some of the major players of the market are Abbott Laboratories Inc., Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche AG, and GlaxoSmithKline PLC, among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence of Cancer
    • 4.2.2 New Product Approvals in Ovarian, Pancreatic, and Prostate Cancers
    • 4.2.3 Increasing Government Initiatives for Cancer Awareness
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Reforms
    • 4.3.2 Price Erosion due to Generic Competition
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Cancer Type
    • 5.1.1 Breast Cancer
    • 5.1.2 Lung Cancer
    • 5.1.3 Colorectal Cancer
    • 5.1.4 Prostate Cancer
    • 5.1.5 Cervical Cancer
    • 5.1.6 Other Cancer Types
  • 5.2 By Drug Type
    • 5.2.1 Carboplatin
    • 5.2.2 Cisplatin
    • 5.2.3 Gemcitabine
    • 5.2.4 Paclitaxel
    • 5.2.5 Doxorubicin
    • 5.2.6 Bevacizumab
    • 5.2.7 Erlotinib
    • 5.2.8 Sunitinib
    • 5.2.9 Everolimusa
    • 5.2.10 Other Drug Types
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories Inc.
    • 6.1.2 Amgen Inc.
    • 6.1.3 AstraZeneca PLC
    • 6.1.4 Baxter International Inc.
    • 6.1.5 Biogen Inc.
    • 6.1.6 Boehringer Ingelheim GmbH
    • 6.1.7 Bristol-Myers Squibb Company
    • 6.1.8 Eli Lilly and Company
    • 6.1.9 F. Hoffmann-La Roche AG
    • 6.1.10 GlaxoSmithKline PLC

7 MARKET OPPORTUNITIES AND FUTURE TRENDS